

**UNIVERSITY OF MIAMI
CURRICULUM VITAE
Silvia R. Delgado, M.D.**

1. Date updated: December 2, 2010

I. PERSONAL

2. Name: Silvia Rosa Delgado

3. Office Phone: 305 243-7078

4. Current Academic Rank: Assistant Professor

6a. Current Track of Appointment: Clinical/ Educational

5. Primary Department: Neurology

6. Secondary or Joint Appointment: None

7. Citizenship: U.S. Citizen

8. Visa Type: N/A

II. HIGHER EDUCATION

9. Institutional (Institution; degree; date conferred):

1985	Medical Doctor, University of Havana, Cuba.
1988	Specialist in Immunology, University of Havana, Cuba.
2001	Residency training program in Neurology, Department of Neurology, Jackson Memorial Hospital, Florida.

POSTGRADUATE TRAINING:

9/1985-10/1988	Residency training program in Basic and Clinical Immunology, University of Havana, Cuba.
10/1993-7/1994	World Health Organization (WHO) Research training in Reproductive Immunology conducted in the Department of Biomedical Sciences, University of Guelph, Guelph, Canada.
8/1994-10/1994	WHO Research training in Human Reproduction conducted in the Fearing Laboratory, Harvard Medical School, Boston.

11/1995-2/1997	Postdoctoral Research Associate. Comprehensive AIDS Program, Department of Psychiatry and Behavioral Sciences, University of Miami, Florida.
7/1997-6/1998	Internship in Internal Medicine, Jersey City Medical Center, Jersey City, NJ.
7/1998-6/2001	Residency training program in Neurology, Department of Neurology, Jackson Memorial Hospital, Florida.
12/2001-12/2002	Postdoctoral Fellow in Multiple Sclerosis, Department of Neurology, University of Miami, Florida.
1/2003-6/2003	Instructor in the Division of Multiple Sclerosis, Department of Neurology, University of Miami, Florida.
6/2003-Present	Assistant Professor, Multiple Sclerosis Division, Department of Neurology, University of Miami, Florida.

12. Non-Institutional (description; dates): N/A

13. Certification, licensure (description; board or agency; dates):

MEDICAL LICENSURE:

4/2001 Florida, No. ME 82273.

BOARD CERTIFICATION:

5/2003 Board-certified in Neurology by the ABPN, certificate No. 52203

III. RESEARCH AND/ OR PROFESSIONAL EXPERIENCE

14. Academic (Institution; rank/ status; dates):

10/1988 –10/1993 Postdoctoral Research Fellow in the field of Reproductive Immunology, Department of Human Reproduction, National Institute of Endocrinology, Havana, Cuba.
 Subject: Study of immunosuppressive factors in human reproductive tissues.
 Advisor: Dr. Lorenzo Mallea, M.D.
 Laboratory techniques performed included:

- Detection of anti- sperm antibodies in human biological fluids by immunobeads.
- Culture of human lymphocytes. Design of models for the study of the immune response in vitro.
- ELISA and RIA.

- Culture of tissue fragments and epithelial cells from human and rat fallopian tubes and epididymis for the study of immunosuppressive factors produced in vitro by these organs and their possible hormonal regulation.
- 11/1993-7/1994 Postdoctoral Research training in Reproductive Immunology, Department of Biomedical Sciences, University of Guelph, Guelph, Canada.
 Subject: Study of apoptosis of uterine natural killer cells from pregnant mice.
 Advisor: Dr. Anne Croy, D.V.M., PhD.
 Laboratory techniques performed included:
- Study of Apoptotic cells in tissues using the TUNEL methodology.
 - Characterization of T lymphocytes and antigen-presenting cells by immunohistochemistry.
 - Isolation of protein and RNA and RT-PCR to analyze expression of IL-2 receptor.
- 8/1994-10/1994 Postdoctoral Research training in Human Reproductive Immunology, Fearing Laboratory, Harvard Medical School, Boston, MA.
 Subject: Study of immunosuppressive factors produced by human fallopian tubes.
 Advisor: Dr. Deborah Anderson, PhD, Director of Fearing Laboratory.
 Laboratory techniques performed included:
- Culture of tissue fragments and epithelial cells from human fallopian tubes for the study of immunosuppressive factors produced in vitro by these organs and their possible hormonal regulation.
- 11/19 95-2/1997 Postdoctoral Research Associate. Comprehensive AIDS Program, Department of Psychiatry and Behavioral Sciences, University of Miami, Florida.
 Subject: Characterization of lymphocyte subpopulations and macrophage antigen expression in CNS and PNS tissues from HIV and non-HIV patients.
 Advisor: Dr. Paul Shapshak, PhD, Director HIV Laboratory.
 Laboratory techniques performed included:
- Characterization of T lymphocytes and antigen-presenting cells by immunohistochemistry.
- 7/1997-6/1998 Internship in Internal Medicine, Jersey City Medical Center, Jersey City, NJ.
 Chief of Service: Dr. Allan Greenberg, M.D.
- 7/1998-6/2001 Residency training program in Neurology, Department of Neurology, Jackson Memorial Hospital, Miami, Florida.
 Chairman: Dr. Walter G. Bradley, D.M., F.R.C.P.

7/2001-10/2001	Private practice in Neurology with the group Garcia-Rivera & Associates, Inc., Miami, Florida.
12/2001-12/2002	Postdoctoral Fellow in Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Miami, Florida. Advisor: Dr. William Sheremata, M.D.
1/2003- 6/2003	Instructor in the Division of Multiple Sclerosis, Department of Neurology , University of Miami, Florida. Advisor: Dr. William Sheremata, M.D.
6/2003- Present	Assistant Professor of Neurology, University of Miami School of Medicine, Miami, Florida.

Teaching Responsibilities:

Neurology residents and medical students on Neurology ward and Consult service at Jackson Memorial Hospital/ UMH (2 months/year) since 2003.
Examiner. Objective Structural Clinical Examination (OSCE) of 3rd year medical students. June, 2003, 2005 and 2009.

15. Hospital Appointments; employers; title; responsibilities; dates:

1/2003- Present	Jackson Memorial Hospital, Attending Physician.
1/2003- Present	Member of the MS Division, Department of Neurology
1/2007- Present	Director of the MS Infusion Center
12/2007-Present	University of Miami Hospital, Attending Physician

16. Military (branch; rank; responsibilities; dates): N/A

IV. PUBLICATIONS (author(s) (in actual precedence of authorship); title; publisher/ journal; date; page numbers)

17. Books and Monographs Published: None

18. Juried or refereed journal articles and exhibitions:

1. Delgado S, Sheremata W, Brown A, McCarthy M. Human T-Lymphotropic Virus type I or II (HTLV-I/II) Associated with Recurrent Longitudinally Extensive Transverse Myelitis (LETM): Two case reports. Accepted for publication in the J of Neuro Virology 2010; 16(3)249-53.
2. Radue EW, Stuart WH, Calabresi PA, et al; SENTINEL Investigators (Delgado S). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010; 292(1-2):28-35

3. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group (Delgado S). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med* 2010; 362(5):402-15.
4. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group (Delgado S). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med* 2010; 362(5):387-401.
5. Papapetropoulos S, Guevara A, Georgiou M, Mitsi G, Singer C, Delgado S. Sarcoidosis with Basal Ganglial Infiltration presenting as Parkinsonism. *BMJ Case Reports* 2009. Doi:10.1136/bcr.07.2008.0569.
6. Delgado S, Baez S, Singer C, Sengun C, Sheremata WA, and Papapetropoulos S. Parkinsonism / dystonia syndrome secondary to multiple sclerosis with anti-basal ganglia antibodies. *Letters to the Editor. Movement Disorders* 2009; 24(2):309-311.
7. Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., et al; for the AFFIRM and SENTINEL Investigators (Delgado S). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. *Neurology* 2007; 68: 1299-1304.
8. Calabresi PA, Giovannoni G, Confavreux C, et al.; AFFIRM and SENTINEL Investigators (Delgado S). The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. *Neurology* 2007; 69(14):1391-403.
9. Rudick RA, Miller D, Hass S, et.; AFFIRM and SENTINEL Investigators (Delgado S). Health-related quality of life in multiple sclerosis: effects of natalizumab. *Ann Neurol* 2007;62(4):307-8.
10. Miller DH, Soon D, Fernando KT, et al. for the AFFIRM Investigators (Delgado S). MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. *Neurology* 2007;68:1390-1401.
11. Wolinsky JS, Narayana PA, O'Connor P, et al. and the PROMiSe Trial Study Group (Delgado S). Glatiramer Acetate in Primary Progressive Multiple Sclerosis: Results of a Multinational, Multicenter, Double-Blind, Placebo-Controlled Trial. *Ann Neurol* 2007;61:14-24.

12. Delgado S, Sheremata W. Role of CD4+ cells in MS. *Neurological Research* 2006; 28: 245-249.
13. Sheremata W, Jy W, Delgado S, Minegar A, Ahn Y. Interferon- β 1a reduces plasma CD31+ Endothelial Microparticles (CD31+EMP) in Multiple Sclerosis. *J Neuroinflammation* 2006;3:23,1-5.
14. Polman CH, O'Connor PW, Havrdova E, et al. for the AFFIRM Investigators (Delgado S). A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. *N Engl J Med* 2006;354:899-910.
15. Rudick RA, Stuart WH, Calabresi PA, et al. for the SENTINEL Investigators (Delgado S). Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. *N Engl J Med* 2006;354:911-23.
16. Sheremata W, and Delgado S. Immunomodulatory drugs for Multiple Sclerosis. *HPE* September/October 2004, 94-95.
17. Delgado S, McCarthy M. Is there a role for Human Herpesvirus-6 in the Course of Multiple Sclerosis? *International Journal of MS Care*. 2002; 4:30-31, 36-39.
18. Shapshak P, Stewart R, Rodriguez P, Dominguez B, Fujimura R, Segal D, Sun N, Delgado S, Petito C. Brain macrophage surface marker expression with HIV-1 infection and drug abuse: a preliminary study. *Journal of Neuro AIDS*. 2002; 2(3):37-50.
19. Delgado S, Shapshak P, Stewart R et al. Heterogeneity of macrophages in the Peripheral Nervous System in HIV-1 infected individuals. *Journal of NeuroAIDS*. 1998; 2:79-97.
20. Bradley W, Shapshak P, Delgado S. et al. Morphometric analysis of the Peripheral Neuropathy of AIDS. *Muscle Nerve*. 1998; 21(9): 1188-95.
21. Shapshak P, Crandall K, Xin Q,...Delgado S. HIV-1 neuropathogenesis and abused drugs: current views, problems, and solutions. In: Sharp B, Eisenstein T, Madden J, Friedman H, eds. *Advances in Experimental Medicine and Biology*. Baton Rouge, CRC Press; 1996; vol 374:171-186.
22. Delgado S, McBey BA, Yamashiro S, et al. Accounting for the peripartum loss of granulated metrial gland cells, a natural killer cell population, from the pregnant mouse uterus. *Journal of Leukocyte Biology*. 1996; 59:262-269.
23. Delgado S, Ramirez K, Mallea L. Efecto inmunosupresor del plasma seminal humano sobre la produccion del LIF "in vitro". *Revista Latinoamericana de Esterilidad y Fertilidad*. 1993; 1.

24. Delgado S, Ramirez K, Mallea L. Efecto inhibitor del plasma seminal humano sobre la proliferacion linfocitaria "in vitro" inducida por fitohemaglutinina. Revista Cubana de Endocrinologia. 1991; 2(1): 10-15.
25. Delgado S, Ramirez K, Mallea L. Epidermal Growth Factor (EGF) is not an index of seminiferous tubular function. Andrologia. 1991; 23:241-244.

19. Other works, publications and Abstracts:

1. Sheremata, W.A., Delgado, SR, Usmani, N., Bedi, G., Brown, A.D., Association of neuromyelitis (NMO) and malignancy. Ann Neurol 2010; (Suppl 1): T97
2. Usmani N., Bedi, G., Brown, A.D., Delgado, S., Sheremata W. Association of paroxysmal dystonia with neuromyelitis optica (NMO). Ann Neurol 2010; (Suppl. 1):T94.
3. Bedi. G., Usmani., N., Delgado., S., Sheremata, W. Prevalence and Ethnic Origin of Patients with Neuromyelitis Optica (NMO) in South Florida. Multiple Sclerosis 2009; 15 (Suppl 2):S34.
4. Bedi, G. Usmani, N., Brown, A.D., Delgado S., Sheremata, W. Treatment outcomes in Neuromyelitis: A retrospective study. Ann Neurol 2009; (Suppl 1): **Check pp**
5. Sheremata, W., Brown, A., Bedi, G., Delgado, S. Neuromyelitis (NMO) with destructive brain lesions in 3 cases. Neurology 2009;72(Suppl. 3):190.189
6. Bedi, G., Brown, A., Delgado, S.R., Usmani, N., Sheremata, W.A. Effect of rituximab on relapse rate and disability in neuromyelitis optica (NMO). Neurology 2009;72 (Suppl3)
7. Delgado, S.R., Sheremata, Brown, A.D., McCarthy, M. Human T-Lymphotropic virus type I/II associated with recurrent longitudinally extensive transverse myelitis resembling neuromyelitis optica. Two case reports. J. Neurovirology. 2009; 15: 24.
8. Bedi, G., Sheremata, W., Brown, A., Usmani, N., Delgado, S.R., Association of serum NMO-Ig with brain lesions in neuromyelitis optica. Keystone Symposium on Molecular and Cellular Biology; Multiple Sclerosis Scientific Program Jan 21, 2009.Abstr #137.

9. Delgado SR, Sheremata WA, Brown AD, McCarthy M. Human T-Lymphotropic Virus Type I/II associated with recurrent longitudinally extensive transverse myelitis resembling Neuromyelitis Optica. Two case reports. Poster 53. 9th International Symposium on Neurovirology, Miami Beach, Florida, June 2-6, 2009.
10. Sheremata W, Bedi GS, Brown AD, Usmani N, Delgado SR. Association of serum NMO-Ig with Brain Lesions in Neuromyelitis Optica. Poster # 310. Keystone Symposia, Santa Fe, New Mexico, January 21-26, 2009.
11. Brown AD, Delgado S, Sheremata W. Rituximab for Neuromyelitis Optica: Experience with nine NMO-IgG positive patients. Poster presentation, Paper # 1791. Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Washington, DC, June 2007.
12. Sheremata W, Jy W, Delgado S, Brown A, Ahn Y. Measurement of plasma CD31+ Endothelial micro particles during Mitoxantrone treatment of progressive Multiple Sclerosis. Abstract # 636. Poster Presentation. ECTRIMS 2006, Sept 27-31, Madrid, Spain.
13. Delgado S, McCarthy M, Sheremata W, and Vidaurre I. Soluble Fas Ligand (sFasL) levels in sera from Multiple Sclerosis patients. Poster presentation. Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Orlando, FL, June 1-5, 2005.
14. Jy W, Delgado S, Minagar A, Ahn Y and Sheremata W. Interferon- β -1a reduces plasma CD31+ endothelial microparticles in MS. *Annals of Neurology* 2003; 54(suppl 7):S60
15. Delgado S, McBey BA, Croy A. Study of the life history and apoptotic cell death of granulated metrial gland (GMG) cells in mice and genotype lpr/lpr. Southern Ontario Reproductive Biology Workshop, 1994, Toronto, Canada.
16. Croy B.A, Delgado S, McBey B.A. Differentiation of the metrial gland in pregnant, genetically mutant mice as a model system for analysis of the natural killer cell lineage. The Society of Natural Immunity 1994 Second Meeting, Taormina, Italy.
17. Co-author. HIV strains, drug abuse, AIDS and the Nervous System. College on Problems of Drug Dependence 1996 Annual Meeting, San Juan, Puerto Rico.
18. Co-author. HIV neuropathogenesis: phylogeny, virus load, and macrophages. Psychiatry Symposium, 1998, Miami, Florida.

20. Other works accepted for publication:

VI. PROFESIONAL

21. Funded Research Performed (include all grants received, identifying the Principal Investigator and amounts and dates of the awards):

On-going Research:

Principal Investigator: A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Protocol # CFTY720D 2309. Sponsor: Novartis Pharmaceuticals Corporation.

Principal Investigator: A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β - 1a (Avonex) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase. Extension Phase. Protocol # CFTY720D 2302 E. Sponsor: Novartis Pharmaceuticals Corporation.

Principal Investigator: A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design. Protocol No: MS-GA-301 (GALA Study). Sponsor: TEVA.

Principal Investigator: 101JC402 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Protocol: STRATIFY-2. Sponsor: Biogen Idec

Clinical Co-Investigator: A multicenter, randomized, rater-blind, parallel-group, active controlled study to evaluate the benefits of switching therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in subjects with Relapsing Remitting Multiple Sclerosis.
Protocol: SURPASS-101MS325.
Sponsor: Biogen Idec, Elan Pharmaceutical.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis. Protocol: 109MS303 [Extension Study].
Sponsor: Biogen Idec
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Multi-Center, Double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing remitting Multiple Sclerosis. Protocol Combi Rx Phase III: (NIH).
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis. Protocol #: 109MS302
Sponsor: Biogen Idec.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: UM Multiple Sclerosis Genetics Registry.
IRDI Award-102902.

Clinical Co-Investigator : A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study

evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis. Protocol # CBAF312A2201
Sponsor: Novartis Pharmaceuticals Corporation.
Principal Investigator: William Sheremata, M.D.

Completed Research:

Principal Investigator: A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β - 1a (Avonex) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase. Protocol # CFTY720D2302.
Sponsor: Novartis Pharmaceuticals Corporation.

Clinical Co-Investigator: A Double blind, Placebo Controlled Multi-center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis. Protocol #: MBP8298-SP-03
Sponsor: BioMS Technology Corp.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: International, Randomized, Multicenter, Phase III Study in Patients with Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blind the Safety, Tolerability, and Efficacy of Betaseron/Betaferon 250 ug (8MIU) and Betaseron/Betaferon 500 ug (16MIU), Both Given Subcutaneously Every Other Day, 2. Rater-Blinded the Safety, Tolerability, and Efficacy of Betaseron/Betaferon S.C. QO. with Copaxone 20 mg S.C. once daily. BEYOND Protocol # 306440: (Berlex and Chiron Laboratories).
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaseron 250 μ g or 500 μ g or open-label Betaseron/Betaseron 250 μ g and

(Phase B) open-label Betaseron/Betaseron 500 µg BEYOND
Follow-up study. Protocol #: 309363
Sponsor: Bayer HealthCare Pharmaceuticals Inc.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab following re-initiation of dosing in Multiple Sclerosis subjects who have completed study C-1801, C-1802, or C- 1803 and a dosing suspension safety evaluation. STRATA Protocol # 101-MS-322. Biogen Idec.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Multicenter, Open-label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in subjects with relapsing forms of Multiple Sclerosis. Protocol # 101-MS- 201. Biogen Idec.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A 24-Week, randomized, double-blind, parallel-group, placebo-controlled, dose finding, safety, tolerability and efficacy study of the human anti-IL-12 Antibody ABT-874 in subjects with Multiple Sclerosis with a 24-Week, Double-blind, Active Extension Phase. Protocol M03-654. Abbott Laboratories.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase ABBOTT. Protocol # M03-654: (Abbott Laboratories).
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803 .Protocol C-1808.
Biogen Idec.
Principal Investigator: William Sheremata, M.D.

Principal Investigator: Determination of soluble Fas Ligand (FasL) concentrations in sera from different subpopulations of MS patients by ELISA. Protocol 03/432A. MS Center at UMSM. Supported by an unrestricted research grant from Berlex.

Clinical Co-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis. Protocol C-1801. (AFFIRM)
Biogen.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex (Interferon beta-1a), in Subjects with Relapsing-Remitting Multiple Sclerosis. Protocol C-1802. (SENTINEL)
Biogen.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: Measurement of Endothelial Microparticles in MS Patients Treated with Interferon beta-1a (Avonex). Biogen.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Multi-National, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Glatiramer Acetate for Injection in Primary Progressive Multiple Sclerosis Patients. Protocol 9008. TEVA Neuroscience, Inc.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon beta-1a) Administered Intramuscularly to Patients with Relapsing/ Remitting Multiple Sclerosis. Protocol C-867.
Biogen.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: A Phase III, Double-Blind, Multicenter, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance[®] with 0.10 mmol/kg of Magnevist[®] in MRI of the Central Nervous System. Protocol MH-109. Bracco Diagnostics.
Principal Investigator: Brian Bowen, M.D.

Clinical Co-Investigator: A Randomized, Rater-Blinded, Multicenter, Parallel-Group Study Comparing the Efficacy and Safety of Betaseron[®] 250 µg Subcutaneously Every Other Day with Avonex[®] 30 µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with AVONEX[®]. Protocol No. 307245. Berlex.
Principal Investigator: William Sheremata, M.D.

Clinical Co-Investigator: Prospective, Open-Label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients. Protocol 031.0007. Immunex Corporation.
Principal Investigator: William Sheremata, M.D.

22. Editorial responsibilities: Assisting Dr. Ashok Verma, M. D. with the Editorials of the Year Book of Neurology and Neurosurgery 2007 and 2008 in the MS section.

23. Professional and Honorary Organizations:

2000- Present Member of the American Academy of Neurology

24. Honors and Awards: None

25. Post-Doctoral Fellowships:

12/2001-12/2002 Postdoctoral Fellow in Multiple Sclerosis, Department of Neurology, University of Miami, Florida.
Advisor: Dr. William Sheremata, M.D.

1/2003-6/2003 Instructor in the Division of Multiple Sclerosis, Department of Neurology, University of Miami, Florida.
Advisor: Dr. William Sheremata, M.D.

26. Other Professional activities (e.g. papers presented; performances; conference proceedings; seminar or conference panel members; etc):

Speaker. Immunopathogenesis of MS. XIV Centroamerican Congress of Neurology. San Jose, Costa Rica, November, 2010.

MS Symposium. An Educational Program for the MS Community. Member of Doctor's Panel Q & A. Miami, Florida, October, 2010.

Neurology Update and Stroke Intensive 2010. Member of Doctor's Panel in the Multiple Sclerosis Session. Miami, Florida, March 2010.

Speaker, Multiple Sclerosis and MS Treatment Overview. Case presentation. Novartis Global Medical Director Meeting, Miami, March, 2009.

Neurology Update and Stroke Intensive 2009. Member of Doctor's Panel in the Multiple Sclerosis Session. Miami, Florida, March 2009.

National MS Society Health Expo. Member of Doctor's Panel Q& A . Davie, Florida, January 2009.

Speaker, MS Overview, Immunopathogenesis, Diagnosis, Role of MRI in the Diagnosis and Treatment of MS, Therapy Selection in MS and Emerging MS Therapies. Novartis Field Medical Team National Meeting, Miami, January, 2009.

Speaker, Considering Treatment Options in Relapsing-Remitting Multiple Sclerosis. Lecture to MS patients from Miami Dade and Broward Counties. Panel discussion and Q&A with Dr. Jeffrey Horstmyer and Dr. Brian Steingo, Miami, March, 2008.

Speaker, Discussing Risks and Benefits of Infusion Therapies in the Treatment of Multiple Sclerosis. Lecture to MS patients from Miami Dade and Broward Counties. Panel Discussion and Q & A with Dr. Angel China and Dr. Brian Steingo, Miami, May 2007.

National MS Society Health Expo. Member of panel Womens's issues and Neurologist Q& A in Spanish and English. Davie, Florida, January 2006.

AAN Meeting. Morphology and Immunohistochemistry of Peripheral Nervous System in AIDS (presentation). Boston, MA, April 1997.

Southern Ontario Reproductive Biology Workshop. Study of the life history and apoptotic cell death of granulated metrial gland (GMG) cells in mice and genotype lpr/lpr (presentation). Toronto, Canada, 1994.

27. Teaching Awards Received: None

28. Teaching Specialization (courses taught):

Speaker, Grand Rounds on Multiple Sclerosis Immunopathogenesis, Department of Neurology, University of Miami, April 2004.

Speaker, Grand Rounds on Apoptosis and Multiple Sclerosis, Department of Neurology, University of Miami, March 2005.

Speaker, Cellular Adhesion Molecules and their role in MS: Natalizumab treatment review, Department of Neurology, University of Miami, February, 2006.

Speaker, Lecture on Cerebellar Disorders, Medical Pathology II course, Department of Physical Therapy, University of Miami, April, 2006.

Speaker, Discussing Risks and Benefits of Infusion Therapies in the Treatment of Multiple Sclerosis. Lecture to MS patients from Miami Dade and Broward Counties. Panel Discussion and Q & A with Dr. Angel Chinaea and Dr. Brian Steingo, Miami, May 2007.

Speaker, Therapy selection in MS I-II, for Neurology residents, Department of Neurology, University of Miami, October, 2007.

Speaker, Considering Treatment Options in Relapsing-Remitting Multiple Sclerosis. Lecture to MS patients from Miami Dade and Broward Counties. Panel discussion and Q&A with Dr. Jeffrey Horstmyer and Dr. Brian Steingo, Miami, March, 2008.

Speaker, Grand Rounds on Multiple Sclerosis Overview, for residents and fellows, Department of Radiology, University of Miami, March 2008.

Speaker, Current Concepts in the Diagnosis and Treatment of Multiple Sclerosis. Lecture to General Neurologists from Miami and Puerto Rico, Miami, Fl, July, 2008.

Speaker, Treatment modalities for MS I and II and Emerging MS therapies for Neurology residents, Department of Neurology, University of Miami, September, 2008.

Speaker, Advances in the Treatment of Multiple Sclerosis. Tysabri Update. New Emerging MS Therapies. Lecture to General Neurologists from Miami Dade County, Miami, FL, October, 2008

Speaker, MS Therapy selection in MS and Tysabri- New Emerging therapies in MS I-II, for Neurology residents, Department of Neurology, University of Miami, September, 2009.

Speaker, Multiple Sclerosis Overview. Fatigue and Pain Management. Educational program for MS patients, Miami, FL, August, 2010.

Speaker, Pathology, Immunopathogenesis and Virology of Multiple Sclerosis for Neurology residents, Department of Neurology, University of Miami, September, 2010.

Speaker, Multiple Sclerosis Treatment: Disease Modifying Therapies and Side Effect Management for Neurology residents, Department of Neurology, University of Miami, September, 2010.

29. Thesis and Dissertation Advising/ Post-doctoral student supervision (Chairman or committee member; topic; student name; date): None

VII. SERVICE

30. Committee and Administrative responsibilities/ Industry Affiliations:

1/2007- Present	Director of the Neurology Infusion Center
9/2009-7/2010	Interim Director of the MS Division, Department of Neurology

31. Community Activities: I participate in multiple community activities through our Parish and different programs of our daughter's school (Saint Theresa School, Coral Gables).